The Tracer Development Specialized Resource (Core B) of this P50 grant application provides the contrast agents, quality control and metabolite analysis in humans and animals to assist the individual research and pilot projects. The activities of the Core will consist of eight primary services: 1) to produce the positron emitting radionuclides 18F and 11C;2) to synthesize anW-1-amino-3-[18F]fluorocyclobutyl-1- carboxylic acid (a/itf-[18F]FACBC) for Research Project #1 and Cores A, C and D;3) to synthesize an 18Flabeled CXCR4 antagonist and an 18F-labeled CCR7 antagonist for Research Project #2 and Cores A, C, and D;4) to synthesize amino terminal fragmented-conjugated iron oxide nanoparticles specific for the cell surface receptor of urokinase plasminogen activator (uPAR) for Research Project #3 and Cores A, C, and D;5) The synthesis of MHI-148-AN conjugates for Research Project #4 and Cores A, C, and D;6) to synthesize the tumor targeted 99mTc-ATF peptide by conjugating 99mTc to the amino-terminal peptide fragment (ATF) of the receptor for urokinase plasminogen activator (uPA) for Pilot Project #1 and Cores A, and D;7) to synthesize 11C-labeled PK11195 and the %-labeled PK11195 antagonist, 1-(2-iodophenyl)-Nmethyl- N-(3-[18F]fluoropropyl)-3-isoquinolinecarboxamide for Pilot Project #4 and Cores A, C and D;and 8) to assist in the preparation of RDRC, IACUC, IND and IRB protocols for regulatory approval of the use of radioactivity in humans and animals for Research Projects #1, 2, 3, and 4, Cores A, C, and D, and Pilot Projects #1, 3, and 4. In this regard, the Specialized Resource (Core B) component is highly integrative, being utilized by all 4 Research Projects and of the Pilot Projects, and having collaborative interactions with each of the other cores.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA128301-05
Application #
8382632
Study Section
Special Emphasis Panel (ZCA1-SRRB-9)
Project Start
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$123,039
Indirect Cost
$43,320
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Akin-Akintayo, Oladunni; Tade, Funmilayo; Mittal, Pardeep et al. (2018) Prospective evaluation of fluciclovine (18F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients. Eur J Radiol 102:1-8
Tian, Zhiqiang; Liu, Lizhi; Zhang, Zhenfeng et al. (2017) A supervoxel-based segmentation method for prostate MR images. Med Phys 44:558-569
Liu, Lizhi; Tian, Zhiqiang; Zhang, Zhenfeng et al. (2016) Computer-aided Detection of Prostate Cancer with MRI: Technology and Applications. Acad Radiol 23:1024-46
Orza, Anamaria; Yang, Yi; Feng, Ting et al. (2016) A nanocomposite of Au-AgI core/shell dimer as a dual-modality contrast agent for x-ray computed tomography and photoacoustic imaging. Med Phys 43:589
Pike, Robert; Lu, Guolan; Wang, Dongsheng et al. (2016) A Minimum Spanning Forest-Based Method for Noninvasive Cancer Detection With Hyperspectral Imaging. IEEE Trans Biomed Eng 63:653-63
Tian, Zhiqiang; Liu, Lizhi; Zhang, Zhenfeng et al. (2016) Superpixel-Based Segmentation for 3D Prostate MR Images. IEEE Trans Med Imaging 35:791-801
Schuster, David M; Nanni, Cristina; Fanti, Stefano (2016) PET Tracers Beyond FDG in Prostate Cancer. Semin Nucl Med 46:507-521
Dance, David R; Sechopoulos, Ioannis (2016) Dosimetry in x-ray-based breast imaging. Phys Med Biol 61:R271-R304
Lu, Guolan; Qin, Xulei; Wang, Dongsheng et al. (2015) Estimation of Tissue Optical Parameters with Hyperspectral Imaging and Spectral Unmixing. Proc SPIE Int Soc Opt Eng 9417:
Kaluzova, Milota; Bouras, Alexandros; Machaidze, Revaz et al. (2015) Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles. Oncotarget 6:8788-806

Showing the most recent 10 out of 83 publications